[144] Ionis Pharmaceuticals, Inc. SEC Filing

Rhea-AI Filing Summary

Ionis Pharmaceuticals (IONS) filed a Form 144 notifying a proposed sale of 3,162 shares of common stock to be executed through Stifel Nicolaus & Company on 09/03/2025. The filing reports an aggregate market value of $192,958.00 based on total shares outstanding of 159,391,229. The shares were acquired by option exercise: 928 shares on 01/03/2022 and 2,234 shares on 01/03/2023, with cash payment noted on the planned sale date. The filing includes the standard seller representation that no material nonpublic information is known to the selling person and indicates no securities sold in the past three months.

Insights

Securities Analyst

TL;DR Insider notified a small planned sale of 3,162 shares, representing a de minimis stake relative to outstanding shares.

The Form 144 documents a proposed sale executed via a broker, with clear acquisition dates and payment method. The aggregate value of about $193k is small versus 159.4 million shares outstanding, suggesting this transaction is unlikely to be materially dilutive or to alter market perception by itself. Disclosure follows standard Rule 144 procedures and indicates no recent sales in the prior three months.

Corporate Governance / Compliance Expert

TL;DR Filing appears procedurally compliant; includes representation regarding absence of material nonpublic information.

The notice names the executing broker and provides required acquisition history and payment details, which supports compliance with Rule 144. The seller affirms no undisclosed material adverse information. The filing does not identify the selling person's name or relationship in the visible extract, but otherwise contains the typical elements for a Section 144 notice.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Stifel Nicolaus & Company Inc 501 N Broadway St. Louis MO 63102	3162	192958.00	159391229	09/03/2025	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	01/03/2022	Option Exercise	Issuer			928	09/03/2025	Cash
Common Stock	01/03/2023	Option Exercise	Issuer			2234	09/03/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What securities does Ionis Pharmaceuticals (IONS) plan to sell?

The filer plans to sell 3,162 shares of Common Stock.

When is the proposed sale of IONS shares scheduled?

The approximate date of sale is listed as 09/03/2025.

What is the aggregate market value of the planned IONS sale?

The filing reports an aggregate market value of $192,958.00.

How and when were the shares being sold acquired?

Shares were acquired by option exercise: 928 on 01/03/2022 and 2,234 on 01/03/2023.

Which broker is handling the proposed sale of IONS shares?

The broker named is Stifel Nicolaus & Company Inc.

Does the filing report any securities sold in the past three months?

The filing states: Nothing to Report for securities sold during the past three months.